ITMI20020269A1 - Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure - Google Patents

Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure

Info

Publication number
ITMI20020269A1
ITMI20020269A1 ITMI20020269A ITMI20020269A1 IT MI20020269 A1 ITMI20020269 A1 IT MI20020269A1 IT MI20020269 A ITMI20020269 A IT MI20020269A IT MI20020269 A1 ITMI20020269 A1 IT MI20020269A1
Authority
IT
Italy
Prior art keywords
steri
omega
patients
ethyl
use
Prior art date
Application number
Other languages
Italian (it)
Original Assignee
Victorix Assets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victorix Assets Ltd filed Critical Victorix Assets Ltd
Priority to ITMI20020269 priority Critical patent/ITMI20020269A1/en
Publication of ITMI20020269D0 publication Critical patent/ITMI20020269D0/en
Publication of ITMI20020269A1 publication Critical patent/ITMI20020269A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
ITMI20020269 2002-02-12 2002-02-12 Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure ITMI20020269A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ITMI20020269 ITMI20020269A1 (en) 2002-02-12 2002-02-12 Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI20020269 ITMI20020269A1 (en) 2002-02-12 2002-02-12 Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure
AU2003210210A AU2003210210A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
PCT/EP2003/001108 WO2003068216A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
EP20030739455 EP1474125A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Publications (2)

Publication Number Publication Date
ITMI20020269D0 ITMI20020269D0 (en) 2002-02-12
ITMI20020269A1 true ITMI20020269A1 (en) 2003-08-12

Family

ID=11449201

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI20020269 ITMI20020269A1 (en) 2002-02-12 2002-02-12 Use of ethyl steri of omega-3 polyunsaturated acids in patients with heart failure

Country Status (4)

Country Link
EP (1) EP1474125A1 (en)
AU (1) AU2003210210A1 (en)
IT (1) ITMI20020269A1 (en)
WO (1) WO2003068216A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20022511A1 (en) * 2002-11-26 2004-05-27 Victorix Assets Ltd Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids in orevenzione of atrial fibrillation.
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
ES2277557B1 (en) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Use of docosahexaenoic acid for the treatment of acid oxidative cell damage.
ES2384701T3 (en) * 2005-12-21 2014-07-02 Brudy Technology, S.L. Use of DHA for the treatment of a pathology associated with oxidative cell damage
KR20140007973A (en) 2009-02-10 2014-01-20 아마린 파마, 인크. Methods of treating hypertriglyceridemia
BRPI1009431A2 (en) * 2009-03-09 2016-03-01 Pronova Biopharma Norge As pre-concentrated pharmaceutical and food supplement, drug delivery systems, method of treatment of at least one health problem in the subject in need thereof and method and system
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2012108379A1 (en) 2011-02-07 2012-08-16 持田製薬株式会社 Therapeutic agent for diastolic congestive heart failure
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
NZ703267A (en) 2012-06-29 2017-01-27 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Essential fatty acids in the prevention of cardiovascular events.
DK1157692T3 (en) * 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Composition of fatty acids containing at least 80 wt% EPA and DHA, their derivatives and pharmaceutical use thereof
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Essential fatty acids in the treatment of heart failure and heart failure

Also Published As

Publication number Publication date
EP1474125A1 (en) 2004-11-10
AU2003210210A1 (en) 2003-09-04
WO2003068216A1 (en) 2003-08-21
ITMI20020269D0 (en) 2002-02-12

Similar Documents

Publication Publication Date Title
ITMI20020078A1 (en) Device usable in the treatment of affections of the respiratory tract
DE60223611D1 (en) Multi-blade balloon catheter to reduce damage to the coated expandable medical implants
DE60305901D1 (en) Device for intradermal administration of drugs
AT431342T (en) Inhibitors of fatty acid amide
RU2017131447A (en) Methods for the preparation and use of an inhibitor sglt2
RU2006110533A (en) Application of modified cyclosporins in the treatment of diseases caused hcv
DE60030403D1 (en) Preparation of 3-hydroxypropionic acid in recombinant organisms
AT418287T (en) Catheter for three-dimensionallen Illustration of electrical activity in blood vessels
AT499144T (en) Generation of multiple therapeutic neurostimulation programs
RU99125607A (en) Regulation of the gas supply or drug to the patient
RU2005124283A (en) The compositions and methods of oral care
DK1501534T3 (en) Of desmopressin orodispersible dosage form
DE60322665D1 (en) Pharmaceutical form with controlled release of a cholesteryl ester transfer protein inhibitors
DK1614418T3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for the treatment of hyperuricemia
DE60322582D1 (en) Surface treatment of medical device
RU2003133446A (en) An oral pharmaceutical composition for the treatment and prevention of heart disease and diseases associated with circulatory disorders
DE602004029496D1 (en) Offbehälter for storage of pharmaceutical fluids
IS7814A (en) Fenetanólamín derivatives in the treatment of respiratory diseases.
RU2007134571A (en) The combination and methods of administration of therapeutic agents and combination therapy
RU2006116267A (en) Lipids containing fatty acids omega-3 and omega-6
RU2002121493A (en) The use of fumaric acid derivatives for the treatment of mitochondrial diseases
DE60325379D1 (en) Composition comprising 6-Ä3- (1-adamantyl) -4-methoxyphenylÜ-2-naphthanoesäure for the treatment of dermatological disorders
DE60324554D1 (en) Ultrasound examination venture with adjustable Controller
DE60333564D1 (en) Patient representation in medical devices
EA200800356A1 (en) Treatment of cholesterol absorption inhibitors based azetidinone and omega-3 fatty acids and their combined preparation